Related Experiment Videos

[Clinical evaluation of CA-50 in cases with colorectal cancer]

O Nishida1, K Ohmori, H Shiroto

  • 1Dept. of Surgery, Hokkaido Univ. School of Med.

Gan No Rinsho. Japan Journal of Cancer Clinics
|April 1, 1989
PubMed

Insights

Serum CA-50 levels are elevated in colorectal cancer patients compared to healthy donors. Combining CA-50 with CA 19-9 and CEA assays improves diagnostic value for colorectal cancer detection.

Area of Science:

  • Oncology
  • Biochemistry

Context:

  • Colorectal cancer (CRC) diagnosis relies on various biomarkers.
  • Accurate and early detection of CRC is crucial for patient outcomes.

Purpose:

  • To evaluate the diagnostic utility of serum carbohydrate antigen 50 (CA-50) in colorectal cancer.
  • To assess the correlation of CA-50 with established tumor markers CA 19-9 and CEA.

Summary:

  • Serum CA-50 was measured in 67 healthy donors and 46 CRC patients using enzyme immunoassay.
  • Mean CA-50 levels were significantly higher in CRC patients (31.7 U/ml) than in healthy donors (10.6 U/ml).
  • Overall sensitivity for CRC was 26.1%, with varying sensitivity across stages (I-V).
  • Strong correlations were observed between CA-50 and CA 19-9 (r=0.82) and CA-50 and CEA (r=0.51).

Impact:

  • Serum CA-50 shows potential as a biomarker for colorectal cancer.
  • Combination assays including CA-50, CA 19-9, and CEA may enhance diagnostic accuracy for colorectal cancer.

Related Concept Videos